Semifield assessment of the runoff potential and environmental risk of the parasiticide drug ivermectin under Mediterranean conditions

Ivermectin is the 22,23-dihydro derivative of avermectin B1, a macrocyclic lactone produced by an actinomycete, Streptomyces avermitilis. It is active at extremely low dosage against a wide variety of nematode and arthropod parasites, apparently by virtue of its action on the mediation of neurotransmission by gamma-aminobutyric acid. It is now in commercial use in various countries for the treatment and control of parasites in cattle, horses, and sheep, and is expected to become available for use in swine and dogs. Since studies with the drug in man are in a preliminary stage, it is not yet known whether ivermectin will be useful in human medicine.

Residues of veterinary parasiticides in dung of treated livestock have nontarget effects on dung-breeding insects and dung degradation. Here, we review the nature and extent of these effects, examine the potential risks associated with different classes of chemicals, and describe how greater awareness of these nontarget effects has resulted in regulatory changes in the registration of veterinary products.